Cargando…
PAD4 and Its Inhibitors in Cancer Progression and Prognosis
The systemic spread of malignancies and the risk of cancer-associated thrombosis are major clinical challenges in cancer therapy worldwide. As an important post-translational modification enzyme, peptidyl arginine deiminase 4 (PAD4) could mediate the citrullination of protein in different components...
Autores principales: | Zhu, Di, Lu, Yu, Wang, Yanming, Wang, Yuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699117/ https://www.ncbi.nlm.nih.gov/pubmed/36365233 http://dx.doi.org/10.3390/pharmaceutics14112414 |
Ejemplares similares
-
TAT-Modified Gold Nanoparticles Enhance the Antitumor Activity of PAD4 Inhibitors
por: Song, Songlin, et al.
Publicado: (2020) -
RGD Peptide and PAD4 Inhibitor-Loaded Gold Nanorods for Chemo-Photothermal Combined Therapy to Inhibit Tumor Growth, Prevent Lung Metastasis and Improve Biosafety
por: Lu, Yu, et al.
Publicado: (2021) -
Self-assembling, pH-responsive nanoflowers for inhibiting PAD4 and neutrophil extracellular trap formation and improving the tumor immune microenvironment
por: Zhu, Di, et al.
Publicado: (2022) -
Peptidylarginine Deiminase Inhibitor Application, Using Cl-Amidine, PAD2, PAD3 and PAD4 Isozyme-Specific Inhibitors in Pancreatic Cancer Cells, Reveals Roles for PAD2 and PAD3 in Cancer Invasion and Modulation of Extracellular Vesicle Signatures
por: Uysal-Onganer, Pinar, et al.
Publicado: (2021) -
Inhibition of Netosis with PAD Inhibitor Attenuates Endotoxin Shock Induced Systemic Inflammation
por: Yao, Huanling, et al.
Publicado: (2022)